News
-
-
-
COMMUNIQUÉ DE PRESSE
MIG Capital Continues Successful Course in 2025 Despite a Challenging Market Environment
MIG Capital AG showcases successful performance in 2025 amid a difficult market landscape. Investments in deep tech and life science startups, strategic growth, and positive company developments propel MIG Capital forward into 2026 -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
MIG Capital leads CHF 7.75 million seed financing for ASTRA Therapeutics
MIG Capital leads CHF 7.75 million seed financing for ASTRA Therapeutics, a Swiss biotech developing precision drugs against eukaryotic pathogens. The investment aims to address the global parasiticide market -